Document is current

Article History

Accepted: 31 March 2025

First Online: 26 April 2025

Declarations

:

: This study was funded by Immunovant Sciences GmbH.

: Thomas Hardy, Su Liang, Philip Tedeschi, and E Lin are employees of Immunovant, Inc. Eliot A. Brinton reports advisor fees from 89bio, Arrowhead Pharmaceuticals, Chiesi, Immunovant, Inc., Ionis Pharmaceuticals, Merck, NewAmsterdam Pharma, Novartis, and Novo Nordisk, and speaking fees from Amgen and Chiesi. Michael H. Davidson has no conflicts of interest that are directly relevant to the content of this article.

: This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice and approved by the appropriate ethics committees. The ethics committee was the WCG IRB (protocol number 20214974). As a phase I trial, the study was not registered in a publicly accessible database.

: All participants provided written informed consent to participate.

: Not applicable.

: Some or all datasets generated and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

: Not applicable.

: TH, SL, PT, and EL contributed to the conceptualization of the study. TH, SL, and EL contributed to the methodology. TH, SL, and PT contributed to the study investigation. EL performed the formal data analysis. TH contributed to the writing of the original manuscript draft. TH, SL, PT, EAB, and MHD contributed to the interpretation of results. All authors contributed to the reviewing and editing of the manuscript and read and approved the final version.